Novel combination therapy with STAR-001 targets the most aggressive and deadliest forms of brain cancer at first progression GBM represents an annual market opportunity of $3 to $5 billion USD with an ...
Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial demonstrated that 92 percent of evaluable patients treated with INB-200 exceeded a median ...
A new research paper was published in Volume 13 of Oncoscience on April 2, 2026, titled "Selective blood–brain barrier ...
Gleolan, a dye used for brain imaging, can help surgeons visualize tumor tissue during surgery for glioblastoma multiforme. Malignant transformation occurs from aggregation of genetic alterations and ...
CDKN2A deletion and radiation sensitivity in IDH-mutant astrocytomas. Expand and pull: A new treatment paradigm for glioblastoma using a long-acting recombinant interleukin-7 and oncolytic viral ...
Glioblastoma multiforme (GBM) stands as a formidable adversary in oncology, characterized by its molecular complexity and relentless progression. Despite advancements, the high degree of tumor ...
Comparative study of six cycles versus twelve cycles of adjuvant temozolomide post concurrent chemoradiation in newly diagnosed glioblastoma. This is an ASCO Meeting Abstract from the 2013 ASCO Annual ...
BEIJING & BURLINGTON, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and ...
(A) Homogenous time-resolved fluorescence (HTRF) assay screening schematic. (B) HTRF assay screening compounds. (C) HTRF assay showed that the effect of FX1, BI-3802, and YK01 blocked the interaction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results